Drug Trial Radar · NCT06767735
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM)
Last checked: Nov 19, 2026Latest source record: Nov 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
580
Planned (sponsor's estimate)
Start
Feb 17, 2025
Primary completion
Aug 1, 2026
Study completion Aug 17, 2026
Sponsor
- Lead sponsor
- Gan & Lee Pharmaceuticals.Industry
- Sponsor type
- Industry
- First posted
- Jan 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will be conducted to compare the efficacy, safety and patient-reported outcome of once-weekly GZR4 and once-daily Insulin Glargine U100 with Non-Insulin Antidiabetic Agents in Insulin-naive Subjects with Type 2 Diabetes Mellitusin.
Conditions
- Diabetes
Interventions
GZR4Drug
GZR4 s.c., once-weekly,treat-to-target dose
Insulin Glargine U100Drug
Insulin Glargine U100 s.c.,once-daily,treat-to-target dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1cTime frame: From baseline (week 0) to week 26
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Gan & Lee Pharmaceuticals Shandong Co., Ltd.
Linyi, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.